Merck’s Keytruda obtains FDA approval as adjuvant therapy for melanoma patients

Keytruda is indicated as an adjuvant therapy for stage IIB or IIC melanoma patients aged 12 years and above. Credit: 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved. Keytruda 100mg/4mL Vial and Carton 2015